| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 5,927 | 8,439 | ||
| Prepaid expenses and other current assets | 1,485 | 1,823 | ||
| Total current assets | 7,412 | 10,262 | ||
| Property and equipment, net | 181 | 200 | ||
| Operating lease right-of-use asset | 1,112 | 1,171 | ||
| Other assets | 29 | 29 | ||
| Total assets | 8,734 | 11,662 | ||
| Accounts payable | 2,525 | 3,907 | ||
| Accrued clinical trials expenses | 1,524 | 1,675 | ||
| Accrued compensation | 1,547 | 546 | ||
| Other accrued expenses | 2,632 | 3,001 | ||
| Total current liabilities | 8,228 | 9,129 | ||
| Convertible notes at fair value, including related party amount of 17,051 and 11,689, at september 30, 2025 and december 31, 2024, respectively | 17,051 | 15,174 | ||
| Operating lease liability | 957 | 1,020 | ||
| Contingent consideration liability | - | 100 | ||
| Warrant liability | 2,338 | 2,122 | ||
| Contingent consideration liability | 32 | 69 | ||
| Total liabilities | 28,606 | 27,514 | ||
| Class a common stock, 0.0001 par value 1,040,000,000 and 500,000,000 shares authorized at september 30, 2025 and december 31, 2024, and 11,643,786 and 555,511 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 413,801 | 413,283 | ||
| Accumulated deficit | -433,682 | -429,144 | ||
| Total stockholders' deficit | -19,872 | -15,852 | ||
| Total liabilities and stockholders' deficit | 8,734 | 11,662 | ||
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)